Article (Scientific journals)
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
Nasreddine, Rakan; Florence, Eric; Yombi, Jean Cyr et al.
2023In HIV Medicine
Peer Reviewed verified by ORBi


Full Text
HIV Medicine - 2023 - Nasreddine - Efficacy durability and tolerability of bictegravir emtricitabine tenofovir.pdf
Author postprint (241.46 kB)

All documents in ORBi are protected by a user license.

Send to


Keywords :
HIV; bictegravir/emtricitabine/tenofovir alafenamide; efficacy; real-world data; tolerability; Health Policy; Infectious Diseases; Pharmacology (medical)
Abstract :
[en] [en] OBJECTIVES: Our objective was to evaluate the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a real-world setting in Belgium. METHODS: This was a retrospective, multicentre cohort study involving adult treatment-naïve (TN) and treatment-experienced (TE) people living with HIV receiving BIC/FTC/TAF between 1 January 2019 and 30 September 2020. The primary outcome was rate of virological suppression (plasma HIV-1 viral load <50 copies/mL; on-treatment analysis) at weeks 24 and 48. The main secondary outcomes included loss of virological suppression (LVS; two consecutive viral loads of >200 copies/mL after being virologically suppressed) by week 48 and analysis of resistance-associated mutations at time of LVS; tolerability of BIC/FTC/TAF over the 48-week study period; and change in weight and proportion of participants reporting a >10% weight gain at week 48. RESULTS: Overall, 2001 participants were included. Through 48 weeks, overall rate of virological suppression was 93.5%, with similar results observed in the following subgroups: age ≥50 years (92.7%), women (92.8%), Black sub-Saharan African (91%), TN (94%), TE (93.2%), and non-suppressed at baseline (86.6%). LVS was observed in 0.7% (n = 14) of participants, with one participant developing resistance-associated mutations to nucleoside reverse transcriptase inhibitors (184 V) and integrase strand transfer inhibitors (263KR). Of the 131 (6.5%) treatment discontinuations, the most common reason was an adverse event (2.4%), with the most frequent being central nervous system/psychiatric (0.4%) and gastrointestinal (0.4%) toxicity. Median weight gain at week 48 was 2 kg (interquartile range -1 to 5), and a >10% weight increase was observed in 11.6% of participants. CONCLUSION: In this large real-world cohort, BIC/FTC/TAF showed excellent virological efficacy in a diverse population of patients with HIV. Rare occurrence of emergent drug resistance was observed, and treatment was well tolerated.
Disciplines :
Immunology & infectious disease
Author, co-author :
Nasreddine, Rakan ;  Saint-Pierre University Hospital, Brussels, Belgium
Florence, Eric;  Institute of Tropical Medicine, Antwerp, Belgium
Yombi, Jean Cyr;  Cliniques Universitaires Saint-Luc, Brussels, Belgium
Henrard, Sophie;  University Clinics of Brussels - Erasme Hospital, Brussels, Belgium
Darcis, Gilles  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service des maladies infectieuses - médecine interne
Van Praet, Jens ;  AZ Sint-Jan Brugge-Oostende, Brugge, Belgium
Vandekerckhove, Linos;  Ghent University Hospital, Ghent, Belgium
Allard, Sabine D;  Universitair Ziekenhuis Brussel, Brussels, Belgium
Demeester, Rémy;  University Hospital of Charleroi, Lodelinsart, Charleroi, Belgium
Messiaen, Peter;  Jessa Hospital, Hasselt, Belgium
Ausselet, Nathalie;  UCL University Hospital Namur-Godinne, Yvoir, Belgium
Delforge, Marc;  Saint-Pierre University Hospital, Brussels, Belgium
De Wit, Stéphane;  Saint-Pierre University Hospital, Brussels, Belgium
Belgian Research on AIDS and HIV Consortium (BREACH)
More authors (4 more) Less
Language :
Title :
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
Publication date :
10 April 2023
Journal title :
HIV Medicine
Publisher :
John Wiley and Sons Inc, England
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
This study was supported by a grant provided by Gilead International.
Available on ORBi :
since 14 June 2023


Number of views
120 (3 by ULiège)
Number of downloads
132 (1 by ULiège)

Scopus citations®
Scopus citations®
without self-citations


Similar publications

Contact ORBi